Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA)

被引：0
|
作者：
Santini, Valeria [1 ]
Fenaux, Pierre [2 ]
Mufti, Ghularn J. [3 ]
Hellstrom-Lindberg, Eva [4 ]
Silverman, Lewis B. [5 ]
List, Alan [6 ]
Gore, Steven D. [7 ]
Seymour, John F. [8 ]
Backstrom, Jay [9 ]
McKenzie, David [9 ]
Beach, C. L. [9 ]
机构：
[1] Azienda Osped Careggi, Florence, Italy
[2] Univ Paris 13, Hop Avicenne, AP HP, Hematol Clin, Bobigny, France
[3] Kings Coll London, Dept Haematol Med, London, England
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[7] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[8] Peter MacCallum Canc Inst, Dept Haematol, Melbourne, Vic, Australia
[9] Celgene, Overland Pk, KS USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：583 / 584
页数：2
相关论文
共 50 条
  • [1] Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*
    Santini, Valeria
    Fenaux, Pierre
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Silverman, Lewis R.
    List, Alan
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    Beach, Charles L.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (02) : 130 - 138
  • [2] Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS
    Gore, S.
    Fenaux, P.
    Santini, V.
    Bennett, J. M.
    Silverman, L. R.
    Seymour, J. F.
    Hellstrom-Lindberg, E.
    Swern, A. S.
    Beach, C. L.
    List, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [4] PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)
    Mufti, G. J.
    Garcia-Manero, G.
    Hovarth, N.
    Lim, Z.
    Quesnel, B.
    Leone, G.
    Bennett, J.
    Sanz, G.
    McKenzie, D.
    Backstrom, J.
    Beach, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 369 - 370
  • [5] Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC)
    Santini, V.
    Silverman, L.
    Seymour, J.
    Fenaux, P.
    Mufti, G.
    Hellstrom-Lindberg, E.
    Sanz, G.
    Finelli, C.
    Backstom, J.
    McKenzie, D.
    Beach, C.
    LEUKEMIA RESEARCH, 2009, 33 : S133 - S133
  • [6] Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)
    Bally, C.
    Ades, L.
    Renneville, A.
    Mozziconacci, M. J.
    Preudhomme, C.
    DeThe, H.
    Lehmann-Che, J.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2013, 37 : S25 - S25
  • [7] The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)
    Zeidan, Amer M.
    Al Ali, Najla H.
    Kharfan-Dabaja, Mohamed A.
    Padron, Eric
    Zhang, Ling
    Epling-Burnette, Pearlie K.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2013, 122 (21)
  • [8] EFFECT OF AZACITIDINE (AZA) ON TRANSFUSION INDEPENDENCE (TI) AND OVERALL SURVIVAL IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Seymour, J.
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Sanz, G.
    List, A. F.
    McKenzie, D.
    Backstrom, J.
    Beach, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 328 - 328
  • [9] Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
    Santini, V.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    List, A. F.
    Silverman, L. R.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Identification of a DNA Methylation Predictive Signature of Overall Survival in Higher-Risk MDS Patients Treated with Azacitidine
    Shi, Tao
    Danilova, Ludmila
    Luo, Xiaolong
    Lucy, Lela M.
    Beach, C. L.
    Cope, Leslie
    Herman, James G.
    MacBeth, Kyle J.
    BLOOD, 2011, 118 (21) : 1630 - 1630
12345